These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29970540)

  • 41. Association Between PD-L1 Expression and Metabolic Activity on
    Takada K; Toyokawa G; Tagawa T; Kohashi K; Akamine T; Takamori S; Hirai F; Shoji F; Okamoto T; Oda Y; Maehara Y
    Anticancer Res; 2017 Dec; 37(12):7073-7082. PubMed ID: 29187498
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Fledelius J; Winther-Larsen A; Khalil AA; Bylov CM; Hjorthaug K; Bertelsen A; Frøkiær J; Meldgaard P
    J Nucl Med; 2017 Dec; 58(12):1931-1937. PubMed ID: 28490472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Variability and Repeatability of Quantitative Uptake Metrics in
    Zhuang M; García DV; Kramer GM; Frings V; Smit EF; Dierckx R; Hoekstra OS; Boellaard R
    J Nucl Med; 2019 May; 60(5):600-607. PubMed ID: 30389824
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic Contrast-Enhanced Perfusion Area-Detector CT: Preliminary Comparison of Diagnostic Performance for N Stage Assessment With FDG PET/CT in Non-Small Cell Lung Cancer.
    Ohno Y; Fujisawa Y; Sugihara N; Kishida Y; Seki S; Koyama H; Yoshikawa T
    AJR Am J Roentgenol; 2017 Nov; 209(5):W253-W262. PubMed ID: 28929810
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
    Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic Value of Volumetric Parameters on Staging and Posttreatment FDG PET/CT in Patients With Stage IV Non-Small Cell Lung Cancer.
    Lee JW; Lee SM; Yun M; Cho A
    Clin Nucl Med; 2016 May; 41(5):347-53. PubMed ID: 26825204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
    Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
    Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histological subtypes of lung adenocarcinoma have differential ¹⁸F-fluorodeoxyglucose uptakes on the positron emission tomography/computed tomography scan.
    Chiu CH; Yeh YC; Lin KH; Wu YC; Lee YC; Chou TY; Tsai CM
    J Thorac Oncol; 2011 Oct; 6(10):1697-703. PubMed ID: 21869716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Information feedback of
    Mu Y; Gui J; Lang Z; Ren C; Yan L; Liu H; Liang J; Feng H
    J Infect Public Health; 2020 Sep; 13(9):1336-1341. PubMed ID: 31289004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
    Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
    Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Ohri N; Bodner WR; Halmos B; Cheng H; Perez-Soler R; Keller SM; Kalnicki S; Garg M
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):372-380. PubMed ID: 28068244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
    Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
    J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of third treatment week as temporal window for assessing responsiveness on repeated FDG-PET-CT scans in Non-Small Cell Lung Cancer patients.
    Lazzeroni M; Uhrdin J; Carvalho S; van Elmpt W; Lambin P; Dasu A; Wersäll P; Toma-Dasu I
    Phys Med; 2018 Feb; 46():45-51. PubMed ID: 29519408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.